The fourth “Asia Summit on Global Health,” hosted by the Hong Kong Trade Development Council, was recently concluded with resounding success. A highlight of the event was Dr. Tom Du’s expert analysis of Hong Kong's future biomedical industry. As the Chairman of Evergreen Therapeutics and a former senior FDA reviewer, Dr. Tom Du, offered valuable perspectives during the summit’s expert roundtable session. This forum garnered significant attention from the Special Administrative Region Government, with notable leaders in attendance, including Chief Executive of the Hong Kong Special Administrative Region John Lee, Deputy Director of the National Health Commission Cao Xuegang, Chairman of the Hong Kong Trade Development Council Lin Zhenyu, and Director of the Department of Health of

June 5, 2023, BojiMed Pharmaceutical Technology Co., Ltd. (stock code: 300404, hereinafter referred to as "BOJIMED"), a well-established domestic CRO listed company, and Shenzhen Evergreen Therapeutics Co. , Ltd. (hereinafter referred to as "Evergreen") Signing a strategic cooperation agreement , the two parties adhere to the principle of "complementary advantages, mutual benefit and win-win", use artificial intelligence (AI) to carry out strategic cooperation in the field of clinical trials, and jointly promote the efficient clinical development and commercialization of innovative drugs in multiple disease fields. By complementing each other's strengths and leveraging the advantages of their respective expert teams, AI can be used to solve bottleneck issues that affect drug research a

On January 5, the "cloud-intelligence Integration, In-depth Life Science" activity of life science area "Intelligent Travel" was successfully held in Shenzhen by Baidu AI Cloud. Nearly 100 representatives from scientific research institutes, gene technology, well-known biopharmaceutical enterprises and Internet enterprises attended the meeting. Shenzhen Evergreen Therapeutics Co., Ltd. (hereinafter referred to as "Evergreen Therapeutics" or "Evergreen") As a leader in the field of AI drug research and development in China, was invited to attend this event and serve as the keynote speaker.                                                Dr. Tao Hu, Director of Pharmaco

On May 28, 2022, Dr. Tom Du, Chairman of Evergreen Therapeutics and Dr. Charles Lee, CMO of Evergreen Therapeutics attended the "First Academic Forum of HwaGen medical thinks markets 2022" sponsored by HwaGen Pharma. The conference was strongly supported by local governments, industry associations and research institutions.Dr. Tom Du making speech Dr. Charles Lee making speech At the meeting, a number of senior experts from the industry witnessed the launch ceremony of the one-stop CRO/CDMO platform of HwaGen Pharma, and discussed the future of small molecule innovative drugs. A roundtable discussion was held on the important role of small molecule new drugs in the fight against COVID-19 and how to better attract financing for innovative drug companies under the current situation

On December 15th, the 4th China Biomedical Industry Chain Innovation and Transformation International Summit and the 4th China Biomedical Industry Chain Innovation Power List Awards Ceremony were jointly hosted by Hangzhou High-tech Zone Government, Yangtze River Delta Data-driven Innovative Biomedical Industry Chain Alliance, and China Biomedical Industry Chain Innovation Transformation Union in Hangzhou. During the conference, Evergreen Therapeutics was recognized as the "Annual Influential Digital Life Health Enterprise of 2023" on the power list for its exceptional contributions to promoting AI clinical practices domestically in recent years.Conference siteThe conference convened both domestic and international academic scientists, research institution leaders, and distinguished corpor

On September 13th, the four-day BIOHK2023 Hong Kong International Biotechnology Forum kicked off at the Hong Kong Convention and Exhibition Center, Supported by the China Association for Science and Technology, the Ministry of Science and Technology, and the Hong Kong Special Administrative Region Government. BIOHK2023 stands as a preeminent international biotechnology event initiated by the esteemed Hong Kong Biotechnology Association, boasting its status as one of Asia's largest conferences in this field. This gathering convenes numerous distinguished experts and academicians across diverse disciplines, including Nobel laureate Dr. Bruce Beutler, Academician Gao Fu from Chinese Academy of Sciences, Academician Han Jisheng, Dr. Wang Yu from former National Center for Disease Control a

On February 4, 2022, Evergreen Therapeutics Co., Ltd. (hereinafter referred to as "Evergreen Therapeutics" or "Evergreen") announced that an oral drug for the treatment of dry macular degeneration with independent intellectual property rights, EG-301, it’s IND was approved by the US FDA and officially entered the phase II clinical trial. EG-301, part of Evergreen Therapeutic’s ophthalmic pipeline, is an oral medication for the treatment of dry maculopathy in patients over 50 years of age. EG-301 has complete safety data in humans and demonstrated efficacy in animal studies. According to statistics, there were about 100 million people with maculopathy in the world in 2020, of which Dry macular disease (AMD) accounted for about 90% of the total number of patients with maculopathy. There

On October 18-19, 2021, Evergreen Therapeutics Co., Ltd. held its first offline meeting at the US headquarters since the outbreak in Bethesda, Maryland. Dr. Du Tao, Chairman of the Board, Dr. Du Xin, Chief Executive Officer, Dr. Li Changqing, Chief Medical Officer, COO Kevin Wang, CFO Julia Lu, Clinical and preclinical Division Director, senior consultant of the company and former senior FDA officer Dr. Florence Houn and other members of Evergreen's consulting team attended the meeting. Figure 1: The first meeting of Evergreen's team, department directors and consultantsUnder the chairmanship of Dr. Du Xin, the meeting reviewed the excellent achievements of Evergreen pharmaceutical in the past two years; Dr. Li Changqing, chief Medical Officer, made a systematic

In celebration of “Golden Autumn”, on October 16, 2021, the FDA Experts Association held the North America Golden Autumn Party at Han Palace in North Bethesda, Maryland. Since its establishment in 2019 on the bank of West Lake in Hangzhou, China, the association has grown stronger under the leadership of its presidents (first President, He Ruyi; current President, Du Tao; President-elect, Li Ning) to become a group of nearly 100 people. Members reside throughout China and the United States, with new members continuously joining, including Liu Ke (Senior VP and Director of Regulatory Affairs & Strategy at Sana Biotechnology) and Wang Yaning (CEO of Createrna Science & Technology). New members have brought fresh

On September 5th, 2019, Dr. Tao Du, the chairman of Evergreen Therapeutics Inc. , went to the famous Meakins-Christie Laboratories (MCL) of McGill University of Canada, known as the most prestigious respiratory disease institute in the world, for academic exchange activities with his team. Dr. Tao Du and team members discussed collaboration in respiratory disease research with Professor James G Martin, former director of MCL and current leader of internal medicine at McGill University School of Medicine. Both determined that research will be carried out in the fields of respiratory rare diseases and asthma and agreed to have in depth cooperation in clinical trials of respiratory rare diseases.Professor James G Martin has 35 years of clinical and scientific experience in the field